Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | PDE2A | O00408 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | HPGDS | O60760 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1325582 | 1.00 | CYP1A2 (0.64) | CYP1A2CYP2C19CYP2D6MMP9PDE2A | |
| SCHEMBL1322600 | 1.00 | CYP1A2 (0.64) | CYP1A2CYP2C19CYP2D6MMP9PDE2A | |
| SCHEMBL1321337 | 0.86 | ALDH1A1 (0.68) | CYP1A2CYP2C19CYP2D6MMP9PDE2A | |
| SCHEMBL1318551 | 0.86 | MMP9 (0.59) | CYP1A2CYP2C19CYP2D6MMP9PDE2A | |
| SCHEMBL1321211 | 0.84 | SMN1; SMN2 (0.67) | CYP1A2CYP2C19CYP2D6MMP9PDE2A | |
| SCHEMBL1321801 | 0.83 | MMP9 (0.57) | CYP1A2CYP2C19CYP2D6MMP9PDE2A | |
| SCHEMBL1321134 | 0.83 | KAT6A (0.48) | CYP1A2CYP2C19CYP2D6MMP9ALDH1A1 | |
| SCHEMBL1320235 | 0.82 | HPGD (0.71) | MMP9PDE2AALDH1A1MEN1KMT2A | |
| SCHEMBL1320898 | 0.82 | KDM4E (0.52) | CYP1A2CYP2C19CYP2D6ALDH1A1LMNA | |
| SCHEMBL16348943 | 0.82 | ALDH1A1 (0.71) | CYP1A2CYP2C19CYP2D6ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021189046-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF SARS-COV-2 | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2021-09-23 | — | — | WO | disclosed |
| US-20110269834-A1 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269834-A1 | COMPOUNDS AND METHODS FOR TREATING RESPIRATORY DISEASES | SARS1, ACE2, ACE | CYP1A2 543/4885CYP2C19 969/4885CYP2D6 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.